EphA2 T-cell epitopes and uses therefor

Details EphA2 T-cell epitopes and uses therefor EphA2 T-cell epitopes and uses therefor

2007-11-20

2007-11-20

Carlson, Karen Cochrane (Department: 1656)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C435S069300, C514S002600, C530S324000

Reexamination Certificate

active

11233796

ABSTRACT:
EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.

REFERENCES:
patent: 5837448 (1998-11-01), Lemke et al.
patent: 5981245 (1999-11-01), Fox et al.
patent: 2006/0034856 (2006-02-01), Kosmatopoulos et al.
patent: WO 03/014303 (2003-02-01), None
patent: WO 03/091383 (2003-11-01), None
Sergel, T.A., et al. 2000 Journal of Virology 74(11): 5101-5107.
Christopher J. Herrem et al. “CD8+ and CD4+ T Cell-Mediated Immunity Against Novel EphA2-Derived Epitopes in Patients with Renal Cell Carcinoma”90thAnniversary Annual Meeting of the American Association of Immunologists, Denver, CO (May 6-10, 2003) Meeting Abstract No. 162.27, p. c333.
“Ephrin Receptor EphA2”,DATABASE UniProt Online!(Oct. 1, 2002) retrieved from EBI accession No. UniProt: Q8N3Z2, pp. 1-2.
“Ephrin Receptor EphA2”,DATABASE UniProt Online!(Oct. 1, 2002) retrieved from EMBL Accession No. BCD037166 abstract, p. 1/1.
Mitchell Koolpe et al. “An Ephrin Mimetic Peptide that Selectively Targets the EphA2 Receptor”Journal of Biological Chemistry, vol. 277, No. 49 (Dec. 6, 2002), pp. 46974-46979.
Kelly Carles-Kinch et al., “Antibody Targeting of the EphA2 Tyrosine Kinase Inhibits Malignant Cell Behavior”Cancer Research, vol. 62, No. 10 (May 15, 2002), pp. 2840-2847.
Tomohide Tatsumi et al. “Disease Stage Variation in CD4+ and CD8+ T-Cell Reactivity to the Receptor Tyrosine Kinase EphA2 in Patients with Renal Cell Carcinoma”Cancer Research, vol. 63, No. 15 (Aug. 1, 2003), pp. 4481-4489.
Vladimir Brusic et al. “Prediction of Promiscuous Peptides that Bind HLA Class I Molecules”Immunology and Cell Biology, vol. 80, No. 3 (Jun. 2002), pp. 280-285.
Anne S. De Groot et al. “From Genome to Vaccine: in silico Predictions, ex vivo Verification”Vaccine, vol. 19, No. 31 (2001) pp. 4385-4395.
Christina Kuttler et al. “An Algorithm for the Prediction of Proteasomal Cleavages”Journal of Molecular Biology, vol. 298, No. 3 (May 5, 2000), pp. 417-429.
Alexander Konrad Nussbaum et al. “PAProC: A Prediction Algorithm for Proteasomal Cleavages Available on the WWW”Immunogenetics, vol. 53, No. 2 (Mar. 2001), pp. 87-94.
Jennifer Walker-Daniels et al. “c-Cbl-Dependent EphA2 Protein Degradation Is Induced by Ligand Binding”Molecular Cancer Research, vol. 1, No. 1 (Nov. 2002), pp. 79-87.
Jennifer Walker-Daniels et al. “Overexpression of the EphA2 Tyrosine Kinase in Prostate Cancer”The Prostate, vol. 41, No. 4 (Dec. 1, 1999), pp. 275-280.
Tomohide Tatsumi et al. “Disease-Associated Bias in T Helper Type 1 (Th1)/Th2 CD4+ T Cell Responses Against MAGE-6 in HLA-DRB1*0401+ Patients with Renal Cell Carcinoma or Melanoma”Journal of Experimental Medicine, vol. 196, No. 5 (Sep. 2, 2002), pp. 619-628.
Singh et al., 2001, “ProPred: prediction of HLA-DR binding sites,” Bioinformatics 17(12):1236-7.
Southwood et al., 1998, “Several common HLA-DR types share largely overlapping peptide binding repertoires,” J. Immunol. 160(7):3363-73.
Andersen et al., 2000, “Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules,” Tissue Antigens 55(6):519-31.
Ebner et al., 1993, “Identification of multiple T cell epitopes on Bet v I, the major birch pollen allergen, using specific T cell clones and overlapping peptides,” J. Immunol. 150(3):1047-54.
Schirle et al., 2001, “Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens,” J. Immunol. Methods 257(1-2):1-16.
Zhong et al., 2003, “Genome-wide characterization of a viral cytotoxic T lymphocyte epitope repertoire,” J. Biol. Chem. 278(46):45135-44.

Affiliated with

Also associated with

Rating

EphA2 T-cell epitopes and uses therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with EphA2 T-cell epitopes and uses therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and EphA2 T-cell epitopes and uses therefor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3820999